In childhood
immune thrombocytopenia (
ITP), anti-platelet
autoantibodies mediate platelet clearance through Fc-γ receptor (FcγR)-bearing phagocytes. In 75% to 90% of patients, the disease has a transient, self-limiting character. Here we characterized how polymorphisms of FcγR genes affect
disease susceptibility, response to
intravenous immunoglobulin (
IVIg) treatment, and long-term recovery from childhood
ITP. Genotyping of the FCGR2/3 locus was performed in 180 children with newly diagnosed
ITP, 22 children with chronic
ITP, and 180 healthy control children by multiplex
ligation-dependent probe amplification. Children with newly diagnosed
ITP were randomly assigned to a single administration of
IVIg or observation, and followed for 1 year (Treatment With or Without
IVIg for Kids With
ITP [TIKI] trial). We defined transient
ITP as a complete recovery (≥100 × 109/L) 3 months after diagnosis, including both self-limiting disease/
IVIg responders and chronic
ITP as absence of a complete recovery at 12 months.
ITP susceptibility, as well as spontaneous recovery and response to
IVIg, was associated with the genetic variants FCGR2C*ORF and FCGR2A*27W and the FCGR2B promoter variant 2B.4. These variants were overrepresented in patients with transient (N = 131), but not chronic (N = 43), disease. The presence of FCGR2C*ORF predisposed to transient
ITP with an odds ratio of 4.7 (95% confidence interval, 1.9-14.3). Chronic
ITP was associated with a deletion of FCGR2C/FCGR3B (copy number region 1) with an odds ratio of 6.2 (95% confidence interval, 1.8-24.7). Taken together, susceptibility to transient and chronic
ITP is distinctly affected by polymorphic variants of FCGR2/3 genes. Our data suggest that genotyping of the FCGR2/3 locus may be useful for prognosis and guidance of treatment decisions in newly diagnosed childhood
ITP.